Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ] - Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011
Tue, June 7, 2011
Mon, June 6, 2011
Sat, June 4, 2011
Fri, June 3, 2011
Thu, June 2, 2011
Wed, June 1, 2011
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011
Tue, May 17, 2011

Somaxon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. jefferies-2011-global-healthcare-conference.html
Published in Health and Fitness on Tuesday, May 31st 2011 at 13:15 GMT by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxona™s president and chief executive officer will present at the Jefferies 2011 Global Healthcare Conference at The Grand Hyatt Hotel in New York City on Monday, June 6, at 9:00 a.m. Eastern Time.

A live webcast of the presentation will be available in the Investor Relations section of the companya™s website under Event Scheduler at [ www.somaxon.com ]. The webcast will be archived and accessible for 90 days following the conference.

To be added to Somaxon Pharmaceuticalsa™ email list, please visit [ http://bit.ly/Somaxon-email-list ].

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxona™s product Silenor®, now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the companya™s web site at [ www.somaxon.com ].


Publication Contributing Sources